1128045-91-9

Basic information

• Product Name: 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate
• Synonyms: 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate
• CAS NO: 1128045-91-9
• Molecular Weight: 313.356
• Mol File: 1128045-91-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate(1128045-91-9)
• EPA Substance Registry System: 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate(1128045-91-9)

Safety Data

• Hazardous Substances Data: 1128045-91-9(Hazardous Substances Data)

Upstream product

• 75907-74-3 2-Pyrazinemethanol,3,5,6-trimethyl 
• 866751-49-7 1‐(3,5,6‐trimethylpyrazin‐2‐yl)methanamine 
• 50-78-2 aspirin 
• 79074-45-6 2-(bromomethyl)-3,5,6-trimethylpyrazine 
• 1128046-47-8 N-((3,5,6-trimethylpyrazin-2-yl)methyl)isoindole-1,3-dione 
• 1124-11-4 Tetramethylpyrazine 
• 5538-51-2 O-acetylsalicyloyl chloride 

Relevant articles and documents

New uses of tetramethylpyrazine derivative in biological nerve protection

The present invention provides applications of a tetramethylpyrazine derivative having a structure represented by a formula 1, or a salt thereof, or a composition containing a tetramethylpyrazine derivative having a structure represented by the formula 1 or a salt thereof in preparation of drugs for prevention or treatment of nervous system diseases, wherein R1 is any one selected from -H, -OCH3 and -OH, R2 is any one selected from -H, -OCH3 and -OH, R3 is any one selected from -H, -OCH3, -OH and -CH3, and R4 is any one selected from -H and -OCH3. The present invention further provides a tetramethylpyrazine derivative having a structure represented by a formula 2, or a salt thereof, or a composition containing a tetramethylpyrazine derivative having a structure represented by the formula 2 or a salt thereof in preparation of drugs for prevention or treatment of nervous system diseases, wherein R1 is any one selected from -H, -OH and -OCOCH3, R2 is any one selected from -H, -OCH3 and -OH, and R3 is any one selected from -H and -OH. The formulas 1 and 2 are defined in the specification.

Ligustrazine derivatives. Part 8: Design, synthesis, and preliminary biological evaluation of novel ligustrazinyl amides as cardiovascular agents

A series of novel Ligustrazinyl amides was designed, synthesized and evaluated for their protective effect onthe injured vascular endothelial cells. The preliminary results demonstrated that some compounds possessed more potentactivities than that of Ligustrazine in stimulating replication of the injured human umbilical vascular endothelial cells(HUVECs) that is damaged by hydrogen peroxide. Among the active compounds, compounds 8i, 8t and 8u exhibited thehighest potency with low EC50 values of 0.037, 0.070 and 0.055 mM, respectively. Structure-activity relationships werebriefly discussed.